Document:

EXHIBIT 4.18

                          REGISTRATION RIGHTS AGREEMENT

      THIS REGISTRATION RIGHTS AGREEMENT, dated as of [see attached schedule],
2001, by and between Biokeys Pharmaceuticals, Inc, a Delaware corporation (the
"Company"), and the undersigned holder (the "Holder") of the Company's
Promissory Notes (the "Notes") and warrants ("Warrants").

                                    RECITALS

      A. The Holder is purchasing from the Company, and the Company desires to
issue and sell to the Holder, (i) Notes, on which the Holder will be receiving
interest in the form of shares of the Company's Common Stock, $.001 par value
("Common Stock") Common Stock, and (ii) Warrants entitling the Holder to
purchase Common Stock upon the exercise thereof as set forth in Agreement (the
"Subscription Agreement") between the Company and the Holder (collectively, with
any other holders purchasing Notes and Warrants under a similar Subscription
Agreement, "Holders").

      B. As partial inducement for the Holder to purchase the Notes and
Warrants, the Company hereby grants the Holder the registration rights set forth
herein, upon the terms and subject to the conditions set forth herein.

      The Company and the Holder hereby agree as follows:

      1. DEFINITIONS. For the purposes of this Agreement:

            (a) The terms "register," "registered" and "registration" refer to a
registration effected by preparing and filing a registration statement or
statements or similar documents in compliance with the Securities Act of 1933,
as amended ("Securities Act"), the Securities Exchange Act of 1934, as amended
("Exchange Act") and pursuant to Rule 415 under the Securities Act or any
successor rule providing for offering securities on a continuous basis ("Rule
415"), and the declaration or ordering of effectiveness of such registration
statement or document by the Securities and Exchange Commission (the "SEC").

            (b) The term "Registerable Securities" means (i) shares of Common
Stock issued in payment interest on the Notes, (ii) shares of Common Stock
issued upon the exercise of the Warrants, and (iii) any Common Stock issued in
replacement of any Notes or Warrants, including any Registerable Securities sold
by a holder of such Registerable Securities in a transaction in which
Registrable Securities and registration rights under this Agreement are
permitted to be assigned.

      2. PIGGYBACK REGISTRATION.

                                       1
<PAGE>

                  (a) Notice. If, beginning at anytime from the earlier of (i)
one year after issuance of the Notes by the Company and (ii) four months after
the next public offering of securities by the Company, and continuing until
December 31, 2006, the Company proposes to file a registration statement under
the Securities Act (a "Registration Statement"), other than a registration on
Form S-8 or Form S-4 with respect to an offering for its own account or for the
account of others of any class of securities of the Company, then, at each such
time, the Company shall give written notice of such intention to file a
Registration Statement (a "Piggyback Notice") to each Holder at least twenty
(20) days before the anticipated filing date of the Registration Statement. The
Piggyback Notice shall describe the intended method of distribution, and shall
offer each Holder the opportunity to register pursuant to such Registration
Statement such Registrable Securities as the Holder may request in writing to
the Company within twenty (20) days after the date the Holder first received the
Piggyback Notice (a "Piggyback Registration"). After receipt of such request
from the Holder, the Company shall take all necessary steps, subject to the
provisions of the following paragraph (b), to include in the Registration
Statement all Registrable Securities which the Company has been so requested to
register by the Holder and to keep such Registration Statement effective until
the later of (i) the sale of all such Registrable Securities and (ii) the date
all such Registrable Securities may be sold without restrictions or limitations
pursuant to Rule 144(k) of the Securities Act. The Company shall be entitled to
withdraw a Registration Statement (not filed pursuant to Section 3 hereof) prior
to its becoming effective, but such withdrawal shall not affect subsequent
rights of Holder.

                  (b) Underwritten Registrations. In a registration pursuant to
this Section 2 involving an underwritten offering, whether or not for sale for
the account of the Company, any request pursuant to this Section 2 may require
that all Registrable Securities be included in such offering on identical terms
and conditions. If the offering is a public offering of the Company's
securities, and if the managing underwriter with respect to such an offering
advises the Company in writing that the inclusion of all the Registrable
Securities which the Holder requested to be included in the Registration
Statement would materially jeopardize the success of the offering, then the
Company shall be required to include in the underwriting only that number, if
any, of Registrable Securities which the underwriter advises the Company in
writing may be sold without materially jeopardizing the offering. Any reduction
to be made by such managing underwriter in the amount of Registrable Securities
to be included in such underwriting shall be made pro rata among each Holder.
Any Holder disapproving of the terms of any such underwriting may elect to
withdraw such Holder's Registrable Securities from registration by written
notice to the Company and the underwriter not later than 15 days prior to the
effective date of any registration.

            3. LIMITATIONS ON THE COMPANY'S OBLIGATIONS. The obligations of the
Company to cause Registrable Securities to be registered under the Securities
Act as provided in this Agreement are subject to each of the following
limitations, conditions and qualifications:

                                       2
<PAGE>

            (a) The Company shall be entitled, for a period of time not to
exceed 45 consecutive days, to postpone the filing of any registration statement
otherwise required to be prepared and filed by it pursuant to Section 2 or 3
above and/or to request that the Holders refrain from effecting any public sales
or distributions of their Registrable Securities if the Board of Directors of
the Company in good faith determines in its reasonable business judgment that
such registration and/or such public sales or distributions would interfere in
any material respect with any financing (other than an underwritten secondary
offering of any securities of the Company), acquisition, corporate
reorganization or other transaction or development involving the Company or any
subsidiary of the Company that in the reasonable good faith business judgment of
such Board is a transaction or development that is or would be material to the
Company (a "Material Development Election"). The Board of Directors of the
Company shall, as promptly as practicable, give the Holders written notice of
any such Material Development Election. In the event of a determination by the
Board of Directors to postpone the filing of a registration statement required
to be filed under Section 2 or 3 hereof, the Company shall be required, if
Holders of at least 50% of the outstanding Notes so request, to file such
registration statement as soon as reasonably practicable after the Board of
Directors of the Company shall determine, in its reasonable business judgment,
that the filing of such registration statement and the offering thereunder shall
not interfere with the aforesaid material transaction or development, but in any
event no later than the end of such 45-day period. In addition, if the Board of
Directors of the Company has requested that the Holders refrain from making
public sales or distributions of their Registrable Securities, such Board shall,
immediately following its determination that the Holders may recommence such
public sales and distributions, notify such Holders in writing of such
determination (but in any event no later than the end of such 45-day period).

      4. REGISTRATION EXPENSES. All expenses incident to a Piggyback
Registration, including, without limitation, all registration and filing fees,
fees and expenses of compliance with securities or blue sky laws, printing
expenses, messenger, telephone and delivery expenses, and fees and,
disbursements of counsel for the Company and counsel for the Holders (but not
more than one counsel for the Holders per registration) and of all independent
public accountants of the Company (including the expenses of any special audit
and "comfort" letters required by or incident to the performance of such
services), underwriting expenses (excluding (a) discounts, commissions or fees
of underwriters, selling brokers, dealer managers or similar securities industry
professionals relating to the distribution of the Registrable Securities which
shall be paid by the selling Holders on a pro rata basis based on the number of
Registrable Securities being sold by them and (b) any stock transfer taxes
incurred with respect to the distribution of the Registrable Securities),
securities acts liability insurance and fees and expenses of other persons or
entities retained by the Company, will be borne by the Company whether or not
any Registration Statement become effective.

      5. HOLDBACK AGREEMENTS. In connection with any underwritten public
offering for the Company's account, each Holder of Registrable Securities agrees
not to effect any public sale or distribution of Common Stock, including a sale
pursuant to Rule 144 or in reliance on any other exemption from registration
under the Securities Act, during the 120 day period beginning on the effective
date of any Registration Statement (except as a participant in such
registration), but only if and to the extent requested in writing (with
reasonable prior written notice) by an underwriter(s) and only if and to the
extent (i) that all executive officers and directors of the Company holding five
(5%) percent or more of the Company's securities, and (ii) all holders of ten
(10%) percent or more of the Company's securities, enter into identical
agreements. Any such agreement shall be in writing in a form satisfactory to a
majority in interest of the Holders.

      6. REGISTRATION PROCEDURES.

            (a) In connection with any registration required or permitted under
this Agreement, the Company covenants and agrees that it will promptly:

                                       3
<PAGE>

                  (i) prepare and file with the Commission a Registration
Statement with respect to the Registrable Securities and use its continuing best
efforts to cause such Registration Statement to become and remain effective;

                  (ii) notify each Holder of Registrable Securities included in
such registration promptly after it shall receive notice thereof, of the time
such Registration Statement has become effective or any supplement to any
prospectus forming a part of such Registration Statement has been filed;

                  (iii) notify each Holder of Registrable Securities included in
such registration promptly of any request by the Commission for the amendment or
supplement of such Registration Statement or prospectus or of a request for
additional information;

                  (iv) prepare and file with the Commission such amendments and
supplements to such Registration Statement and the prospectus used in connection
therewith and such other documents necessary to comply with the Securities Act,
the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the
rules and regulations promulgated under the Securities Act and the Exchange Act,
as may be necessary to keep such Registration Statement filed pursuant to this
Agreement effective for a period of not less than twelve months and comply with
the provisions of the Securities Act with respect to the disposition of all
securities covered by such Registration Statement during such period in
accordance with the intended methods of disposition by the sellers thereof set
forth in such Registration Statement;

                  (v) furnish to each Holder of Registrable Securities included
in such registration such number of copies of such Registration Statement, each
amendment and supplement thereto, the prospectus included in such Registration
Statement (including each preliminary prospectus) and such other documents,
including correspondence with the Commission, as such Holder may reasonably
request in order to facilitate the disposition of the Registrable Securities
owned by such Holder;

                  (vi) concurrently with the effectiveness of the Registration
Statement under the Securities Act, qualify the Registrable Securities under
such other securities or "blue sky" laws of such jurisdictions as each Holder
reasonably may request, and do any and all other acts and things necessary to
enable each Holder to consummate the sale of the Registrable Securities owned by
such Holder; provided that the Company shall not be required in connection with
this paragraph (vi) to qualify as a foreign corporation or execute a general
consent to service of process in any jurisdiction where the Company is not then
so qualified or subject to service of process or to subject the Company to
income taxation in any jurisdiction where it is not then so subject;

                  (vii) notify each Holder of Registrable Securities included in
such registration, at any time when a prospectus relating thereto, is required
to be delivered under the Securities Act, of the happening of any event as a
result of which the prospectus included in such Registration Statement contains
an untrue statement of a material fact or omits any fact necessary to make any
statement therein not misleading in light of the circumstances in which such
statement is made, and prepare and furnish to such Holder a reasonable number of
copies of a supplement to or amendment of such prospectus so that, as thereafter
delivered to the purchasers of such Registrable Securities, such prospectus will
not contain an untrue statement of a material fact or omit to state any fact
necessary to make the statements therein not misleading in light of the
circumstances in which they are made;

                                       4
<PAGE>

                  (viii) advise each Holder of Registrable Securities included
in such registration promptly after it shall receive notice or obtain knowledge
of the issuance of any stop order by the Commission suspending the effectiveness
of any such Registration Statement or the initiation or threat of any proceeding
for that purpose and promptly use its reasonable best efforts to prevent the
issuance of any stop order or to obtain its withdrawal if such stop order should
be issued;

                  (ix) use its reasonable best efforts to cause all such
Registrable Securities to be listed on each securities exchange or reported on
each consolidated reporting system on which similar securities issued by the
Company are then listed or reported, as the case may be;

                  (x) provide a transfer agent and registrar for all such
Registrable Securities not later than the effective date of such Registration
Statement;

                  (xi) allow each Holder of Registrable Securities included in
such registration to participate in the preparation of the Registration
Statement, each prospectus included therein or filed with the Commission and
each amendment or supplement thereto and make available for inspection by each
Holder, any underwriter participating in any disposition pursuant to such
Registration Statement, and any attorney, accountant or other agent retained by
such Holder or such underwriter, all financial and other records, pertinent
corporate documents and properties of the Company and cause the Company's
officers, directors, employees and independent accountants to supply all
information reasonably requested by such Holder, underwriter, attorney,
accountant or agent in connection with such Registration Statement, subject to
the right of the Company to require confidentiality agreements in a form
reasonably acceptable to the Company and such Holder; and

                  (xii) furnish, at the request of any Holder or Holders
requesting registration of Registrable Securities pursuant to this Agreement, on
the date that such Registrable Securities are delivered to the underwriters for
the sale pursuant to such registration or, if such Registrable Securities are
not being sold through underwriters, on the date that the registration statement
with respect to such Registrable Securities becomes effective, an opinion, dated
such date, of the independent counsel representing the Company for the purposes
of such registration, addressed to the underwriters, if any, and to the Holder
or Holders making such request, covering such legal matters with respect to the
registration in respect of which such opinion is being given as the Holder
requesting such opinion may reasonably request; provided such matters are of a
nature that legal counsel are normally required to opine upon in connection with
such a registration or offering, and a letter dated such date, from the
independent certified public accountants of the Company, addressed to the
underwriters, if any, and to the Holder or Holder making such request, stating
that they are independent certified public accountants within the meaning of the
Securities Act and that in the opinion of such accountants, the financial
statements and other financial data of the Company included in the registration
statement or prospectus, or any amendment or supplement thereto, comply as to
form in all material respects with the applicable accounting requirements of the
Securities Act. Such letter from the independent certified public accountants
shall additionally cover such other financial matters with respect to the
registration in respect of which such letter is being given as the Holder
requesting such letter may reasonably request; provided such matters are of a
nature that accountants are normally required to opine upon in connection with
such registration.

                                       5
<PAGE>

            (b) The Company may require each Holder participating in a
registration hereunder to furnish the Company such information regarding such
Holder and the distribution of such Registrable Securities as the Company may
from time to time reasonably request in writing and as shall be required by law
to effect such registration. Each holder, as a condition of participating in
such registration, shall furnish such information, which shall be complete,
correct and not misleading.

            (c) The Holder or Holders who include Registrable Securities in any
registration under this Agreement shall distribute those Registrable Securities
in a manner consistent with the distribution described in the relevant
registration statement.

      7. RULE 144. After a Public Offering, the Company shall take all actions
reasonably necessary to enable the Holder to sell Registrable Securities without
registration under the Securities Act within the limitation of the exemptions
provided by (a) Rule 144 under the Securities Act, as such Rule may be amended
from time to time, or (b) any similar rule or regulation hereafter adopted by
the Commission, including, without limiting the generality of the foregoing,
filing on a timely basis all reports required to be filed under the Exchange
Act, but shall not be liable for any damages resulting from an inability of a
Holder to rely on Rule 144 if the Company was not timely in its filings because
of circumstances beyond its reasonable control. Upon the request of any Holder,
the Company will deliver to such Holder a written statement as to whether it has
complied with such requirements and shall provide such Holder with such publicly
filed documents of the Company as are reasonably requested by such Holder in
connection with such sale.

      8. INDEMNIFICATION.

            (a) Indemnification by the Company. In the event of any registration
of any of the Registrable Securities under the Securities Act pursuant to this
Agreement, the Company will indemnify and hold harmless each Holder
participating in the registration, its directors, officers and partners and each
underwriter involved in such registration and each other person, if any, who
controls each selling Holder or underwriter within the meaning of the Securities
Act or the Exchange Act against any losses, claims, damages or liabilities,
joint or several, to which each selling Holder or its officers, directors, or
partners or underwriter may become subject insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based
upon any untrue statement or alleged untrue statement of any material fact
contained in any Registration Statement under which such Registrable Securities
were registered under the Securities Act, any preliminary prospectus or final
prospectus contained in such Registration Statement, or any amendment or
supplement to such Registration Statement, or arise out of or are based upon the
omission or alleged omission to state a material fact required to be stated
therein or necessary to make the statements therein not misleading in light of
the circumstances in which they are made, and will reimburse such selling
Holder, its officers, directors, and partners and such underwriter and each such
controlling person for any legal or any other expenses reasonably incurred by
any of them as they are incurred in connection with investigating or defending
any such loss, claim, damage, liability or action; provided, however, that the
Company will not be liable to any selling Holder or its officers, directors, or
partners, or underwriter and controlling persons in any such case to the extent

                                       6
<PAGE>

that any such loss, claim, damage or liability arises out of or is based upon
any untrue statement or omission made in such Registration Statement,
preliminary prospectus or final prospectus, or any such amendment or supplement
thereto, (i) in reliance upon and in conformity with information furnished to
the Company, in writing, by or on behalf of such selling Holder or its officers,
directors, or partners, or underwriter and controlling persons, specifically for
use in the preparation of such Registration Statement, preliminary prospectus or
final prospectus or amendment or supplement thereto, or (ii) where such untrue
statement or omission or alleged untrue statement or omission (A) was corrected
in a subsequent final prospectus delivered in sufficient number to the selling
Holder and with sufficient time to permit distribution by such selling Holder,
(B) such selling Holder failed to so distribute such subsequent final
prospectus, and (C) to the extent such distribution would have avoided the
applicable loss, claim, damage, liability or action.

            (b) Indemnification by the Holder. In the event of any registration
of any of the Registrable Securities under the Securities Act pursuant to this
Agreement, each selling Holder, severally and not jointly, will indemnify and
hold harmless the Company, each of its directors, and officers, each underwriter
involved in such registration, each other selling Holder and their respective
officers, directors, and partners and each person, if any, who controls the
Company or any such underwriter or selling Holder within the meaning of the
Securities Act or the Exchange Act, against any losses, claims, damages or
liabilities (or actions in respect thereof), to which the Company, such
directors and officers, such underwriter or selling Holder or its respective
officers, directors, stockholders or partners or controlling person may become
subject, insofar as such losses, claims, damages or liabilities (or actions in
respect thereof) arise out of or are based upon any untrue statement or alleged
untrue statement of a material fact contained in any Registration Statement
under which such Registrable Securities were registered under the Securities
Act, any preliminary prospectus or final prospectus contained in such
Registration Statement, or any amendment or supplement to such Registration
Statement, or arise out of or are based upon any omission or alleged omission to
state a material fact required to be stated therein or necessary to make the
statements therein not misleading in light of the circumstances in which they
are made, and will reimburse the Company, the underwriters, each other selling
Holder and their respective officers, directors, stockholders, partners and
controlling person for any legal or any other expenses reasonably incurred by
any of them in connection with investigating or defending any such loss, claim,
damage, liability or action, if the statement or omission was made in reliance
upon and in conformity with information furnished in writing to the Company by
or on behalf of such selling Holder or its officers, directors, stockholders or
partners or controlling persons, specifically for use in connection with the
preparation of such Registration Statement, preliminary prospectus or final
prospectus or amendment or supplement thereto; provided, however, that the
maximum obligation of each selling Holder for indemnification shall be limited
to the net proceeds received by it from the sale of Registrable Securities
pursuant to such Registration Statement.

                                       7
<PAGE>

            (c) Required Notices. Each party entitled to indemnification under
this Section 8 (the "Indemnified Party") shall give notice to the party required
to provide indemnification (the "Indemnifying Party") promptly after the
Indemnified Party has actual knowledge of any claim as to which indemnity may be
sought and, with respect to third party claims, shall permit the Indemnifying
Party to assume the defense of any such claim or any litigation resulting from
it, provided that counsel for the Indemnifying Party who shall conduct the
defense of such claim or litigation must be approved by the Indemnified Party
(whose approval shall not unreasonably be withheld), and provided further that
the failure of any Indemnified Party to give notice as provided in this Section
8(c) shall not relieve the Indemnifying Party of its obligations under Sections
8(a) or (b), as the case maybe except to the extent such Indemnifying Party was
actually prejudiced thereby. The Indemnified Party shall have the right to
employ its own counsel in any claim or litigation, but, with respect to third
party claims or litigation, the fees and expenses of counsel shall be at the
expense of such Indemnified Party, when and as incurred, unless the Indemnified
Party shall have reasonably concluded that there may be a conflict of interest
between the Indemnifying Party and the Indemnified Party in the conduct of the
defense of such claim or litigation (in which case the Indemnifying Party shall
not have the right to direct the defense of such claim or litigation on behalf
of the Indemnified Party), or the Indemnifying Party shall fail, within a
reasonable time after notice of the claim, to have given written notice of its
intention to assume such defense, and to have employed counsel to assume the
defense of such claim or litigation, or the Indemnifying Party fails timely and
actively to assume or to continue the defense of such claim. No Indemnifying
Party, in the defense of any claim or litigation, shall, without the consent of
the Indemnified Party, consent to entry of any judgment or enter into any
settlement that does not include as an unconditional term the giving by the
claimant or plaintiff to such Indemnified Party of a release from all liability
in respect of such third party claim or litigation. In no event shall an
Indemnified Party consent to any entry of any judgment in a third party claim or
litigation, or settle a third party claim or litigation without the prior
written consent of the Indemnifying Party unless the Indemnifying Party fails to
timely give notice of its intention to assume defense or timely and actively to
assume and continue such defense.

      9. ASSIGNABILITY. The rights granted in this Agreement may be assigned in
whole or in part by a Holder, but only along with a permitted assignment of
Registrable Securities by such Holder. Nothing contained herein shall be deemed
to permit an assignment, transfer or other disposition of Notes or Warrants in
violation of the terms and conditions of the Subscription Agreement.

      10. NOTICES.

            (a) All notices, consents, requests, demands and other
communications required or permitted to be given under this Agreement shall be
in writing and delivered personally, receipt acknowledged, or mailed by
registered or certified mail, postage prepaid, return receipt requested, or sent
by overnight express delivery service, or given by telecopier transmission and
confirmed by one of the preceding notice delivery methods, addressed to the
parties hereto as follows (or to such other addresses as any of the parties
hereto shall specify by notice given in accordance with this provision):

                                       8
<PAGE>

                  If to the Company to:
                           Biokeys Pharmaceuticals, Inc.
                           333 N. Sam Houston Parkway
                           Suite 1035
                           Houston, Texas 77060

or at such other address as it may have furnished in writing to the Holder of
Registrable Securities at the time outstanding, or

                  If to the Holder of any Registrable Securities:

                           To the address of such Holder as recorded in the
                           stockholder records of the Company.

            (b) All such notices, consents, requests, demands and other
communications shall be deemed given when personally delivered as aforesaid, or,
if mailed or sent by overnight service as aforesaid, on the third business day
after the mailing thereof or on the day actually received, if earlier, except
for a notice of a change of address which shall be effective only upon receipt.

      11. AMENDMENT, WAIVER AND TERMINATION. This Agreement maybe amended, and
the observance of any term of this Agreement may be waived, but only with the
written consent of the Company and the Holder. No delay on the part of any party
in the exercise of any right, power or remedy shall operate as a waiver thereof,
nor shall any single or partial exercise by any party of any right, power or
remedy preclude any other or further exercise thereof, or the exercise of any
other right, power or remedy.

      12. COUNTERPARTS. One or more counterparts of this Agreement may be signed
by the parties, each of which shall be an original but all of which together
shall constitute one and the same instrument.

      13. BINDING EFFECT. This Agreement shall be binding upon and inure to the
benefit of the parties hereto and their respective successors, heirs, personal
representatives, administrators, executors and permitted assigns. Nothing
contained in this Agreement is intended to confer upon any person or entity,
other than the parties hereto or their respective successors, heirs, personal
representatives, administrators, executors or permitted assigns, any rights,
benefits, obligations remedies or liabilities under or by reason of this
Agreement.

                                       9
<PAGE>

      14. GOVERNING LAW. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York with respect to contracts made
and to be fully performed therein, without regard to the conflicts of laws
principles thereof. The parties hereto hereby agree that any suit or proceeding
arising under this Agreement, or in connection with the consummation of the
transactions contemplated hereby, shall be brought solely in a federal or state
court located in the City, County and State of New York. By its execution
hereof, the Company hereby consents and irrevocably submits to the in personam
jurisdiction of the federal and state courts located in the City, County and
State of New York and agrees that any process in any suit or proceeding
commenced in such courts under this Agreement may be served upon it personally
or by certified or registered mail, return receipt requested, or by Federal
Express or other courier service, with the same force and effect as if
personally served upon it in New York City (or in the city or county in which
such other court is located). The parties hereto each waive any claim that any
such jurisdiction is not a convenient forum for any such suit or proceeding and
any defense of lack of in personam jurisdiction with respect thereto.

      15. INVALIDITY OF PROVISIONS. If any provision of this Agreement is or
becomes invalid, illegal or unenforceable in any respect, the validity, legality
and enforceability of the remaining provisions contained herein shall not be
affected thereby.

      16. HEADINGS. The headings in this Agreement are for convenience of
reference only and shall not be deemed to alter or affect the meaning or
interpretation of any provisions hereof.

      IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the
date first set forth above.

                                                 BIOKEYS PHARMACEUTICALS, INC.

                                                 By: /s/ Warren Lau
                                                     ---------------------------
                                                     President

                                                     HOLDER:

                                                     (see schedule on next page)
                                                     ---------------------------
                                                     Print Name
                                                     ---------------------------
                                                     Position (if applicable):
                                                     ---------------------------

                                       10
<PAGE>

                               SCHEDULE OF HOLDERS

      Each of the persons listed below executed this form of Registration Rights
Agreement as a "Holder" effective as of the date set forth opposite such persons
name below:

HOLDER                                            EFFECTIVE DATE
-------------------------------------------------------------------
Ernst Pernet                                      November 14, 2001
-------------------------------------------------------------------
Robert J. Neborsky, MD, Inc.
 Combination Retirement Trust U/T/A 11/30/82      October 29, 2001
-------------------------------------------------------------------

                                       11EXHIBIT 4.19

THIS WARRANT HAS BEEN, AND THE SHARES OF COMMON STOCK WHICH MAY BE RECEIVED
PURSUANT TO THE EXERCISE OF THIS WARRANT WILL BE, ACQUIRED SOLELY FOR INVESTMENT
AND NOT WITH A VIEW TO, OR FOR RESALE IN CONNECTION WITH, ANY DISTRIBUTION
THEREOF. NEITHER THIS WARRANT NOR SUCH SHARES (TOGETHER, THE "SECURITIES") HAVE
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY
STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE,
PLEDGED OR HYPOTHECATED IN THE ABSENCE OF SUCH REGISTRATION OR AN OPINION OF
COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH
DISPOSITION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS
OF THE ACT AND OF ANY APPLICABLE STATE SECURITIES LAWS.

NO. W-__

                        WARRANT TO PURCHASE COMMON STOCK

                                   __________

      THIS CERTIFIES THAT, for good and valuable consideration, [SEE ATTACHED
SCHEDULE FOR NAMES OF HOLDERS] (the "HOLDER") is entitled to subscribe for and
purchase from Biokeys Pharmaceuticals, Inc., a Delaware corporation (the
"COMPANY"), [SEE ATTACHED SCHEDULE FOR NUMBER OF SHARES] fully paid and
nonassessable shares of Common Stock, par value $0.001 per share ("COMMON
STOCK"), of the Company (as adjusted pursuant to Section 3 hereof) (the "WARRANT
SHARES") at a price per share equal to Sixty Cents ($0.60) (as adjusted pursuant
to Section 3 hereof) (the "EXERCISE PRICE"), subject to the provisions and upon
the terms and conditions hereinafter set forth.

1.   METHOD OF EXERCISE; PAYMENT.

      (A) Exercise Period. The purchase rights represented by this Warrant may
be exercised by the Holder during the term of this Warrant (as set forth in
Section 9 hereof) in whole or in part, at any time after the Commencement Date,
as defined below, by the surrender of this Warrant (with the notice of exercise
form attached hereto as Exhibit A (the "NOTICE OF EXERCISE") duly executed) at
the principal office of the Company.

      (B) Cash Exercise. Upon exercise of this Warrant, the Holder shall pay the
Company an amount equal to the Exercise Price multiplied by the number of
Warrant Shares being purchased, by wire transfer or certified check payable to
the order of the Company. The person or persons in whose name(s) any
certificate(s) representing the Warrant Shares shall be issuable upon exercise
of this Warrant shall be deemed to have become the holder(s) of record of, and
shall be treated for all purposes as the record holder(s) of, the Warrant Shares
represented thereby (and such Warrant Shares shall be deemed to have been
issued) immediately prior to the close of business on the date or dates upon
which this Warrant is exercised.

                                       1
<PAGE>

      (C) Stock Certificates. In the event of any exercise of the rights
represented by this Warrant, certificates for the Warrant Shares so purchased
shall be delivered to the Holder within a reasonable time after exercise and,
unless this Warrant has been fully exercised or has expired, a new Warrant
representing the shares with respect to which this Warrant shall not have been
exercised shall also be issued to the Holder within such time.

2. STOCK FULLY PAID; RESERVATION OF SHARES. All of the Warrant Shares issuable
upon the exercise of the rights represented by this Warrant will, upon issuance
and receipt of the Exercise Price therefor, be fully paid and nonassessable, and
free from all preemptive rights, rights of first refusal or first offer, taxes,
liens and charges with respect to the issuance thereof. During the period within
which the rights represented by this Warrant may be exercised, the Company shall
at all times have authorized and reserved for issuance a sufficient number of
Warrant Shares to provide for the exercise of the rights represented by this
Warrant.

3. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF SHARES. The number and kind of
Warrant Shares purchasable upon the exercise of this Warrant and the Exercise
Price therefor shall be subject to adjustment from time to time upon the
occurrence of certain events, as follows:

      (A) Reclassification, Consolidation or Reorganization. In case of any
reclassification of the Common Stock (other than a change in par value, or as a
result of a subdivision or combination), or in case of any consolidation or
merger of the Company with or into another corporation (other than a Change of
Control, as defined below) (any of which is a "REORGANIZATION TRANSACTION"), the
Company, or such successor corporation as the case may be, shall execute a new
warrant, providing that the holder of this Warrant shall have the right to
exercise such new warrant, and procure upon such exercise and payment of the
same aggregate Exercise Price, in lieu of the Warrant Shares theretofore
issuable upon exercise of this Warrant, the kind and amount of shares of stock,
other securities, money and property as would be payable for the Warrant Shares
issuable upon exercise of this Warrant as if such Warrant Shares were
outstanding on the consummation of the Reorganization Transaction. For purposes
of this Warrant, the term "CHANGE OF CONTROL" shall mean (i) any acquisition of
the Company by means of merger, acquisition, or other form of corporate
reorganization in which outstanding shares of the Company are exchanged for
securities or other consideration issued, or caused to be issued, by the
acquiring corporation or its subsidiary or parent (other than a reincorporation
transaction or change of domicile) and pursuant to which the holders of the
outstanding voting securities of the Company immediately prior to such
consolidation, merger or other transaction fail to hold equity securities
representing a majority of the voting power of the Company or surviving entity
immediately following such consolidation, merger or other transaction (excluding
voting securities of the acquiring corporation held by such holders prior to
such transaction) or (ii) a sale of all or substantially all of the assets of
the Company.

      (B) Stock Splits, Dividends and Combinations. In the event that the
Company shall at any time subdivide the outstanding shares of Common Stock, or
shall issue a stock dividend on its outstanding shares of Common Stock, the
number of Warrant Shares issuable upon exercise of this Warrant immediately
prior to such subdivision or to the issuance of such stock dividend shall be
proportionately increased, and the Exercise Price shall be proportionately
decreased, and in the event that the Company shall at any time combine the
outstanding shares of Common Stock, the number of Warrant Shares issuable upon
exercise of this Warrant immediately prior to such combination shall be
proportionately decreased, and the Exercise Price shall be proportionately
increased, effective at the close of business on the date of such subdivision,
stock dividend or combination, as the case may be.

                                       2
<PAGE>

4. TRANSFER OF WARRANT. This Warrant may only be transferred in compliance with
federal and state securities laws and, except as provided below, may not be
transferred except with the prior written consent of the Company, which shall
not be unreasonably withheld or delayed, and any purported transfer without such
prior written consent shall be null and void; provided, however, that the
Company may withhold its consent to transfer or assignment of this Warrant to
any person or entity who is deemed to be a competitor or prospective competitor
of the Company, such determination to be made in the reasonable judgment of the
Board.

5. CONDITION TO EXERCISE OF WARRANT. Each certificate evidencing the Warrant
Shares issued upon exercise of this Warrant shall be stamped or imprinted with a
legend substantially in the following form:

      THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR
      INVESTMENT AND NOT WITH A VIEW TO, OR FOR RESALE IN CONNECTION WITH, ANY
      DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
      ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY STATE SECURITIES LAWS. SUCH
      SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN
      THE ABSENCE OF SUCH REGISTRATION OR AN OPINION OF COUNSEL SATISFACTORY TO
      THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED UNDER
      THE ACT OR UNLESS SOLD PURSUANT TO RULE 144 OF SUCH ACT.

6. FRACTIONAL SHARES. No fractional Warrant Shares will be issued in connection
with any exercise hereunder, but in lieu of such fractional shares the Company
shall make a cash payment therefor upon the basis of the Exercise Price then in
effect.

7. REPRESENTATIONS AND WARRANTIES BY THE HOLDER. The Holder represents and
warrants to the Company as follows:

      (A) This Warrant is being acquired for the Holder's own account, for
investment and not with a view to, or for resale in connection with, any
distribution or public offering thereof within the meaning of the Securities Act
of 1933, as amended (the "SECURITIES ACT"). Upon exercise of this Warrant, the
Holder shall, if so requested by the Company, confirm in writing, in a form
reasonably satisfactory to the Company, that the Warrant Shares issuable upon
exercise of this Warrant are being acquired for investment and not with a view
toward distribution or resale. The Holder is an "accredited investor" within the
meaning of the Securities Act.

                                       3
<PAGE>

      (B) The Holder understands that this Warrant and the Warrant Shares have
not been registered under the Securities Act by reason of their issuance in a
transaction exempt from the registration and prospectus delivery requirements of
the Securities Act pursuant to Section 4(2) thereof and that the Company's
reliance upon such exemption is predicated, in part, upon the Holder's
representations and warranties set forth in this Agreement. The Holder
understands that this Warrant and the Warrant Shares must be held by the Holder
indefinitely, and that the Holder must therefore bear the economic risk of such
investment indefinitely, unless a subsequent disposition thereof is registered
under the Securities Act or is exempted from such registration. The Holder
further understands that this Warrant and the Warrant Shares have not been
registered under the securities laws of any state.

      (C) The Holder acknowledges that it is acquiring this Warrant without
being offered or furnished any offering literature or prospectus. The Holder
understands that neither the United States Securities and Exchange Commission,
nor any governmental agency charged with the administration of the securities
laws of any state nor any other governmental agency has passed upon or reviewed
the merits or qualifications of, or recommended or approved the issuance of this
Warrant or the Warrant Shares.

      (D) The Holder understands that, except as provided in Section 10 of this
Warrant, the Company is under no obligation to register this Warrant or the
Warrant Shares.

      (E) The Holder is a bona fide resident and domiciliary (not a temporary or
transient resident) of the state indicated in the signature page hereto and the
Holder has no present intention of becoming a resident of any other state or
jurisdiction.

      (F) The Holder has such knowledge and experience in financial and business
matters that it is capable of evaluating the merits and risks of the purchase of
this Warrant and the Warrant Shares purchasable pursuant to the terms of this
Warrant and of protecting its interests in connection therewith. The Holder is
able to bear the economic risk of the purchase of the Warrant Shares pursuant to
the terms of this Warrant.

8. RIGHTS OF STOCKHOLDERS. No holder of this Warrant shall be entitled, as a
Warrant holder, to vote or receive dividends or be deemed the holder of Warrant
Shares or any other securities of the Company which may at any time be issuable
on the exercise hereof for any purpose, nor shall anything contained herein be
construed to confer upon the Holder any of the rights of a stockholder of the
Company or any right to vote for the election of directors or upon any matter
submitted to stockholders at any meeting thereof, or to give or withhold consent
to any corporate action (whether upon any recapitalization, issuance of stock,
reclassification of stock, change of par value, consolidation, merger,
conveyance, or otherwise) or to receive notice of meetings, or to receive
dividends or subscription rights or otherwise with respect to the Warrant Shares
until this Warrant shall have been exercised and the Warrant Shares purchasable
upon the exercise hereof shall have become deliverable, as provided herein.

                                       4
<PAGE>

9.   TERM OF WARRANT.

      (A) This Warrant shall become exercisable on the date of issuance set
forth below (the "COMMENCEMENT DATE") and shall no longer be exercisable as of
the earlier of (i) 5:00 p.m., San Diego, California local time, on the date that
is the three-year anniversary of the Commencement Date; (ii) immediately prior
to a Change of Control and (iii) 5:00 p.m., San Diego, California local time, on
the Call Termination Date (as defined below).

      (B) Notwithstanding anything herein to the contrary, at any time after the
Commencement Date, if the closing price of one share of Common Stock quoted in
the over-the-counter market summary, the Bulletin Board Exchange, the Nasdaq
National Market or the closing price quoted on a national securities exchange,
whichever is applicable, is greater than 200% of the Exercise Price for a period
of 20 consecutive trading days, then thereafter the Company shall have the right
(the "COMPANY TERMINATION RIGHT"), exercisable at the Company's sole discretion,
to terminate this Warrant with at least 10-days' prior written notice (the
"TERMINATION NOTICE") which Termination Notice shall state the date this Warrant
shall terminate (the "CALL TERMINATION DATE"); provided, however, that the
Company may not exercise the Company Termination Right unless a registration
statement registering the Warrant Stock has been declared effective and is
effective from the date of delivery of the Termination Notice until the Call
Termination Date, provided, further, that if this Warrant is terminated pursuant
to this Section 9(b), then the Company shall use commercially reasonable efforts
to maintain the effectiveness of a registration statement registering the
Warrant Stock until the date that is 15 days after the Call Termination Date or,
if earlier, the date the Holder shall have sold all its Warrant Shares covered
by such registration statement.

10.  REGISTRATION RIGHTS.

      (A) Piggy-back Rights. If (but without any obligation to do so) the
Company proposes to register any shares of Common Stock solely for cash pursuant
to a registration statement under the Securities Act, other than a registration
solely in connection with a transaction under Rule 145 promulgated under the
Securities Act (a "PUBLIC OFFERING"), the Company shall promptly give the Holder
written notice of such Public Offering, at least 10 business days prior to the
filing of the registration statement under the Securities Act regarding such
Public Offering. Upon the written request of the Holder given within 5 business
days after delivery of such written notice by the Company, the Company shall,
subject to the provisions of Section 10(b) below, use its best efforts to cause
to be registered under the Securities Act all of the Warrant Shares that the
Holder has requested to be registered.

      (B) Underwriting. If the registration statement under which the Company
gives notice under this Section 10 is for an underwritten Public Offering, the
Company shall so advise the Holder. The right of the Holder to registration
pursuant to Section 10(a) above shall be conditioned upon the Holder's
participation in such underwriting and the inclusion of the Warrant Shares in
the underwriting to the extent provided herein. The Holder shall (together with
the Company and any other holders of Company securities distributing their
securities through such underwriting) enter into an underwriting agreement in
customary form with the underwriter or underwriters selected for underwriting by
the Company. Notwithstanding any other provision of this Section 10, if the
underwriter determines that marketing factors require a limitation of the number
of shares to be underwritten, the underwriter may exclude some or all of the
Warrant Shares from such registration and underwriting.

                                       5
<PAGE>

      (C) Furnish Information. It shall be a condition to the Company's
obligations to take any action under this Section 10 that the Holder shall
furnish to the Company such information regarding itself, the Warrant Shares,
and the intended method of disposition of such Warrant Shares as shall be
required to effect the registration of any Warrant Shares. In that connection,
the Holder shall be required to represent to the Company that all such
information which is given is both complete and accurate in all material
respects when made.

      (D) Delay of Registration. The Holder shall have no right to obtain or
seek an injunction restraining or otherwise delaying any such registration as
the result of any controversy that might arise with respect to the
interpretation or implementation of this Section 10.

      (E) Termination of Registration Rights. The Company shall have no
obligation to register Warrant Shares pursuant to this Section 10 with respect
to any request or requests made by any Holder on or after that date which is one
year after the date such Warrant Shares were deemed to be acquired for purposes
of determining the holding period of such Warrant Shares under Rule 144 of the
Act.

11.  MISCELLANEOUS.

      (A) This Warrant is being delivered in the state of California and shall
be construed and enforced in accordance with and governed by the laws of the
state of California, without giving effect to principles of conflicts of laws.

      (B) The headings in this Warrant are for purposes of reference only, and
shall not limit or otherwise affect any of the terms hereof.

      (C) The terms of this Warrant shall be binding upon and shall inure to the
benefit of any successors or assigns of the Company and of the Holder and of the
Warrant Shares issued or issuable upon the exercise hereof.

      (D) Any notice provided for or permitted under this Warrant shall be
treated as having been given (a) upon receipt, when delivered personally, (b)
upon receipt, when sent by confirmed facsimile or telecopy, (c) one day after
sending, when sent by commercial overnight courier with written verification of
receipt, or (d) three business days after deposit with the United States Postal
Service, when mailed postage prepaid by certified or registered mail, return
receipt requested, addressed (a) if to the Company, at 9948 Hibert Street, Suite
100, San Diego, CA 92131, facsimile: (858) 271-9678, Attention: Nicholas J.
Virca, or (b) if to the Holder, at such address or facsimile number as the
Holder shall have furnished to the Company in writing, or at such other place of
which the other party has been notified in accordance with the provisions of
this Section 11(d).

      (E) This Warrant constitutes the full and entire understanding and
agreement between the parties with regard to the subjects hereof.

                                       6
<PAGE>

      (F) Upon receipt of evidence reasonably satisfactory to the Company of the
loss, theft, destruction or mutilation of this Warrant and, in the case of any
such loss, theft or destruction, upon delivery of an indemnity agreement
reasonably satisfactory in form and amount to the Company or, in the case of any
such mutilation, upon surrender and cancellation of such Warrant, the Company at
the Holder's expense will execute and deliver to the holder of record, in lieu
thereof, a new Warrant of like date and tenor.

      (G) This Warrant and any provision hereof may be amended, waived or
terminated only by an instrument in writing signed by the Company and the
Holder.

      (H) Receipt of this Warrant by the Holder shall constitute acceptance of
and agreement to the foregoing terms and conditions.

                            [Signature page follows.]

                                       7
<PAGE>

      IN WITNESS WHEREOF, the Company has caused this Warrant to be signed by
its duly authorized officer.

         Issued May 28, 2003

                             BIOKEYS PHARMACEUTICALS, INC.

                             By:      /s/ Nicholas J. Virca
                                      ------------------------------------------
                             Name:    Nicholas J. Virca

                             Title:   President and Chief Executive Officer

                             [SEE ATTACHED SCHEDULE]

                             By:      __________________________________________

                             Name:    __________________________________________

                             Title:   __________________________________________

                             Address:   ________________________________________

                                        ________________________________________

                             Facsimile: ________________________________________

                                       8
<PAGE>

                                    EXHIBIT A

                               NOTICE OF EXERCISE

TO:   Biokeys Pharmaceuticals, Inc.
      9948 Hibert Street, Suite 100
      San Diego, CA  92131

      The undersigned hereby elects to purchase ____________ shares of Common
Stock, par value $0.001 per share, of the Company ("COMMON STOCK") pursuant to
the terms of Section 1(b) of the Warrant to Purchase Common Stock dated May ___,
2003 (the "WARRANT"), and tenders herewith payment of the purchase price of such
shares in full.

      Please issue a certificate or certificates representing said _________
shares of Common Stock in the name of the undersigned or in such other name as
is specified below:

                           Name:      _________________________________

                           Address:   _________________________________

                                      _________________________________

      The undersigned hereby represents and warrants that the aforesaid shares
of Common Stock are being acquired for the account of the undersigned for
investment and not with a view to, or for resale, in connection with the
distribution thereof, and that the undersigned has no present intention of
distributing or reselling such shares, and that all representations and
warranties of the undersigned set forth in Section 7 of the Warrant are true and
correct as of the date hereof.

                              [NAME OF WARRANT HOLDER]

                              By:      _________________________________________

                              Name:    _________________________________________

                              Title:   _________________________________________

                              Date:    _________________________________________

                                       9
<PAGE>

                           SCHEDULE OF WARRANTHOLDERS

      ADVENTRX Pharmaceuticals, Inc. issued this form of Warrant to Purchase
Common Stock to each of the persons listed below for the purchase of up to the
number of shares of Common Stock listed opposite such person's name below.

HOLDER                                                      WARRANT NO.  SHARES
--------------------------------------------------------------------------------
Balkrishna E. Shagrithaya                                    WC-107      37,500
Centrum Bank AG                                              WC-108       1,500
EFG Private Bank S.A.                                        WC-109         750
James Ladner                                                 WC-110       7,495
Schroder & Co. Bank AG                                       WC-111      48,000
Hans Gaverstrom                                              WC-112       3,728
The Prudent Bear Fund                                        WC-113     375,000
Franco Merlo                                                 WC-114       2,989
Tek Investments, LP                                          WC-115     375,000
Robert A. Melnick                                            WC-116      37,500
Robert Neborsky, M.D., Inc. Combination Retirement Trust     WC-117      15,000
Deborah Young, MD APC Employees Retirement Trust             WC-118       7,500
Mark Collins                                                 WC-119      18,750
Clariden Investments Ltd.                                    WC-120      16,500
Paul H. Robbins                                              WC-121      37,500
Michael Loew                                                 WC-122      37,500
Schroder & Co. Bank AG                                       WC-123      45,000
Ernst Pernet                                                 WC-124      15,000
David Wiener Revocable Trust -96                             WC-125      15,000
Roger S. Sherman                                             WC-126       7,500
Jillian E. and Richard J. Boldway                            WC-127       7,500
Sabbatical Ventures, LLC                                     WC-128      15,000
Michael Kooper                                               WC-129      56,250
Julie A. Gegner                                              WC-130         750
Hans Gaverstroem                                             WC-131      14,980
X Mark Fund LP                                               WC-132      75,000
X Mark Fund Ltd.                                             WC-133     150,000
Richard Melnick                                              WC-134      56,250
Richard P. and Carolyn M. Burgoon                            WC-135       1,500
Michael Kooper                                               WC-136      17,969
SDS Merchant Fund, LP                                        WC-137     187,500
Katherine Ashforth Wiener                                    WC-138      15,000
Andrew J. Maffey                                             WC-139      30,000
Clifford Ross                                                WC-140      15,000
Robert Wexler                                                WC-141       7,500
Richard Melnick                                              WC-142      45,000
Caroline A. Levine                                           WC-143      11,250
Lawrence Levine                                              WC-144       3,750
Eric T. Singer                                               WC-145      30,000
Global eMedicine                                             WC-146      37,500
Burnham Hill Holdings, LLC                                   WC-147      30,000
Jim Simpson                                                  WC-148       7,500
Richard & Ricki Hoffman                                      WC-149      15,000
Jason Adelman                                                WC-154      20,046
Mathew Balk                                                  WC-155      12,231
Richard Melnick                                              WC-150      33,750
Richard Melnick                                              WC-151      50,000
Craig Pierson                                                WC-152      50,000
Eric Singer                                                  WC-156       5,572
Rob Nathan                                                   WC-157       5,573
Jonathan Balk                                                WC-165      32,250
Rob Nathan*                                                  WC-200      12,231

*     The Warrant to Purchase Common Stock issued to Rob Nathan was issued
      October 3, 2003.

                                       10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}]]